Boehringer Ingelheim and Eli Lilly will launch two outcomes trials within the next 12 months investigating their jointly developed diabetes medicine Jardiance (empagliflozin) as a treatment for people with chronic heart failure – enrolling patients both with and without type 2 diabetes.
Jardiance was the first diabetes treatment to demonstrate a reduction in the risk of cardiovascular (CV) death in the dedicated...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
